Abstract: Methods of treating or reducing the risk of obesity and/or obesite-related disorders, e.g., metabolic syndrome, hepatic and non-hepatic steatosis, and diabetes, using C20orf27 proteins or nucleic acids.

Abstract: Methods of treating or reducing the risk of obesity and/or obesity-related disorders, e.g., metabolic syndrome, hepatic and non-hepatic steatosis, and diabetes, using C20orf27 proteins or nucleic acids.

Abstract: Methods for altering leptin resistance and the hormonal control of energy balance, and methods for treating obesity and diabetes, as well as promoting weight gain, using batotin and batotin inhibitors.

Abstract: Methods of treating or reducing the risk of obesity and/or obesite-related disorders, e.g., metabolic syndrome, hepatic and non-hepatic steatosis, and diabetes, using C20orf27 proteins or nucleic acids.

Abstract: Disclosed herein are methods for enhancing one or more effects of exercise in a subject by administering a PPAR? agonist (e.g., GW1516) to the subject in combination with an exercise program. Also disclosed are gene expression profiles unique to the combination of agonist-induced PPAR? activation and exercise. Such profiles are useful, at least, in methods for identifying the use of performance-enhancing drugs in exercised subjects (such as, professional or athletes). Direct interactions between PPAR? and exercised-induced kinases (e.g., AMPK or its subunits, AMPK ?1 and/or AMPK ?2) also are disclosed. Such protein-protein interactions provide new targets for identification of useful compounds.

Abstract: Disclosed herein are methods for enhancing one or more effects of exercise in a subject by administering a PPAR? agonist (e.g., GW1516) to the subject in combination with an exercise program. Also disclosed are gene expression profiles unique to the combination of agonist-induced PPAR? activation and exercise. Such profiles are useful, at least, in methods for identifying the use of performance-enhancing drugs in exercised subjects (such as, professional or athletes). Direct interactions between PPAR? and exercised-induced kinases (e.g., AMPK or its subunits, AMPK ?1 and/or AMPK ?2) also are disclosed. Such protein-protein interactions provide new targets for identification of useful compounds.